Natixis Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.11M | Sell |
23,956
-3,804
| -14% | -$183K | ﹤0.01% | 1445 |
|
|
2026
Q1 | $1.44M | Buy |
27,760
+3,366
| +14% | +$171K | ﹤0.01% | 1230 |
|
|
2025
Q4 | $1.21M | Buy |
24,394
+125
| +0.5% | +$6.08K | ﹤0.01% | 1205 |
|
|
2025
Q3 | $1.16M | Sell |
24,269
-18,239
| -43% | -$734K | ﹤0.01% | 1265 |
|
|
2025
Q2 | $1.34M | Buy |
42,508
+2,117
| +5% | +$67.8K | ﹤0.01% | 1210 |
|
|
2025
Q1 | $1.32M | Buy |
40,391
+1,324
| +3% | +$46.9K | ﹤0.01% | 1200 |
|
|
2024
Q4 | $1.41M | Sell |
39,067
-251
| -0.6% | -$8.84K | ﹤0.01% | 1203 |
|
|
2024
Q3 | $1.23M | Buy |
39,318
+5,113
| +15% | +$160K | ﹤0.01% | 1233 |
|
|
2024
Q2 | $915K | Sell |
34,205
-3,676
| -10% | -$107K | ﹤0.01% | 1282 |
|
|
2024
Q1 | $1.29M | Buy |
37,881
+1,122
| +3% | +$33.4K | ﹤0.01% | 1148 |
|
|
2023
Q4 | $1.06M | Buy |
36,759
+1,081
| +3% | +$28.7K | ﹤0.01% | 1188 |
|
|
2023
Q3 | $984K | Buy |
35,678
+1,647
| +5% | +$50.1K | ﹤0.01% | 1179 |
|
|
2023
Q2 | $1.02M | Sell |
34,031
-2,713
| -7% | -$94.9K | ﹤0.01% | 1151 |
|
|
2023
Q1 | $1.33M | Buy |
36,744
+1,194
| +3% | +$45.9K | ﹤0.01% | 1067 |
|
|
2022
Q4 | $1.27M | Buy |
35,550
+755
| +2% | +$26.2K | ﹤0.01% | 1068 |
|
|
2022
Q3 | $1.18M | Buy |
34,795
+1,497
| +4% | +$48.7K | 0.01% | 1056 |
|
|
2022
Q2 | $963K | Buy |
33,298
+2,172
| +7% | +$62.2K | ﹤0.01% | 1140 |
|
|
2022
Q1 | $1.01M | Buy |
31,126
+4,129
| +15% | +$127K | ﹤0.01% | 1132 |
|
|
2021
Q4 | $787K | Buy |
26,997
+4,953
| +22% | +$150K | ﹤0.01% | 1161 |
|
|
2021
Q3 | $588K | Buy |
22,044
+2,419
| +12% | +$64.9K | ﹤0.01% | 1186 |
|
|
2021
Q2 | $604K | Buy |
19,625
+3,525
| +22% | +$108K | ﹤0.01% | 1187 |
|
|
2021
Q1 | $421K | Sell |
16,100
-96
| -0.6% | -$2.69K | ﹤0.01% | 1190 |
|
|
2020
Q4 | $407K | Buy |
16,196
+3,774
| +30% | +$81.2K | ﹤0.01% | 1145 |
|
|
2020
Q3 | $259K | Sell |
12,422
-1,623
| -12% | -$36.8K | ﹤0.01% | 1120 |
|
|
2020
Q2 | $334K | Buy |
+14,045
| New | +$310K | ﹤0.01% | 1115 |
|
|
2020
Q1 | – | Sell |
-52,152
| Closed | -$1.24M | – | 1224 |
|
|
2019
Q4 | $1.24M | Sell |
52,152
-12,793
| -20% | -$311K | 0.01% | 937 |
|
|
2019
Q3 | $1.78M | Sell |
64,945
-14,932
| -19% | -$442K | 0.01% | 799 |
|
|
2019
Q2 | $2.64M | Buy |
+79,877
| New | +$2.74M | 0.02% | 686 |
|
|
2016
Q4 | – | Sell |
-25,746
| Closed | -$637K | – | 1038 |
|
|
2016
Q3 | $637K | Buy |
25,746
+2,045
| +9% | +$46.3K | 0.01% | 874 |
|
|
2016
Q2 | $483K | Buy |
+23,701
| New | +$420K | 0.01% | 890 |
|
Other funds holding SUPN
AC
NAMI
SIMG
Natixis Advisors's SUPN Position: Q2 2026 in Review
Natixis Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 14% in Q2 2026, selling an estimated $183K and leaving 23,956 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1445.
Natixis Advisors first reported a position in SUPN in Q2 2016 and has held it in 30 quarters since. The position peaked at $2.64M in Q2 2019. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- Natixis Advisors held 23,956 shares of Supernus Pharmaceuticals worth $1.11M as of Q2 2026.
- Natixis Advisors sold 3,804 Supernus Pharmaceuticals shares in Q2 2026, an estimated $183K.
- Supernus Pharmaceuticals made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1445 holding.
- Natixis Advisors first reported a position in Supernus Pharmaceuticals in Q2 2016 and has held it in 30 quarters since.
- Natixis Advisors's Supernus Pharmaceuticals position peaked at $2.64M in Q2 2019.
- 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.